Early Successes in an Open Access, Provincially Funded Hepatitis C Treatment Program in Prince Edward Island

Early Successes in an Open Access, Provincially Funded Hepatitis C Treatment Program in Prince Edward Island

Show other versions (1)

Introduction. The availability of curative hepatitis C therapies has created an opportunity to improve treatment delivery and access. Local providers, government, industry, and community groups in Prince Edward Island developed an innovative province-wide care model. Our goal was to describe the fir...

Full description

Bibliographic Details
Main Authors:	Jordan W. Francheville, Robin Rankin, Jeremy Beck, Connie Hoare, Stefanie Materniak, Greg German, Lisa Barrett, Natalie Bunimov-Wall, Daniel Smyth
Format:	Article
Language:	English
Published:	Elsevier 2018-03-01
Series:	Annals of Hepatology
Subjects:	Hepatitis C virus Direct-acting antivirals Real-world Sustained virologic response Health plan implementation
Online Access:	http://www.sciencedirect.com/science/article/pii/S1665268119301541

Similar Items

Early Successes in an Open Access, Provincially Funded Hepatitis C Treatment Program in Prince Edward Island
by: Jordan W. Francheville, et al.
Published: (2017-09-01)

Ombitasvir, paritaprevir, and ritonavir with peginterferon-α2a plus ribavirin in treatment-experienced patients with chronic hepatitis C virus genotype 1 infection
by: Bernstein D, et al.
Published: (2019-02-01)

Interferon-Free Regimen: Equally Effective in Treatment Naive and Experienced HCV Patients
by: Crina Fofiu, et al.
Published: (2019-01-01)

Eradication of hepatitis C virus infection disclosing a previously hidden, underlying autoimmune hepatitis: Autoimmune hepatitis and HCV
by: Valentina Cacciato, et al.
Published: (2020-03-01)

The road to elimination of hepatitis C: analysis of cures versus new infections in 91 countries
by: Andrew M. Hill, et al.
Published: (2017-07-01)

Factors Associated with Large Renal Function Decline in Patients with Chronic Hepatitis C Successfully Treated with Direct-Acting Antiviral Therapy
by: Chun-Hsien Chen, et al.
Published: (2023-01-01)

Efficacy of generic sofosbuvir with daclatasvir compared to sofosbuvir/ledipasvir in genotype 4 hepatitis C virus: A prospective comparison with historical control
by: Hala Joharji, et al.
Published: (2023-01-01)

Patients with Hepatitis C on Direct-Acting Antiviral Agents' Response to the Elimination Program in Dammam City within 2018-2020
by: Manal S. Fawzy, et al.
Published: (2022-09-01)

Recurrence of hepatitis C virus after treatment with pegylated interferon and direct acting antivirals in Punjab Pakistan
by: M. N. Raza, et al.
Published: (2021-12-01)

Hepatitis C direct‐acting antiviral outcomes in patients 75 years and older
by: Parmvir Parmar, et al.
Published: (2021-02-01)

A validation study of after direct‐acting antivirals recommendation for surveillance score for the development of hepatocellular carcinoma in patients with hepatitis C virus infection who had received direct‐acting antiviral therapy and achieved sustained virological response
by: Toshifumi Tada, et al.
Published: (2022-01-01)

Big and Little Feet Provincial Profiles: Prince Edward Island
by: Sarah Dobson, et al.
Published: (2017-09-01)

Big and Little Feet Provincial Profiles: Prince Edward Island
by: Sarah Dobson, et al.
Published: (2017-09-01)

Big and Little Feet Provincial Profiles: Prince Edward Island
by: Sarah Dobson, et al.
Published: (2017-09-01)

Extrahepatic Cancer Risk in Patients with Hepatitis C Virus Infection Treated with Direct-Acting Antivirals
by: Joji Tani, et al.
Published: (2024-09-01)

Prediction of Hepatocellular Carcinoma Development in Korean Patients after Hepatitis C Cure with Direct-Acting Antivirals
by: Hyeyeon Hong, et al.
Published: (2024-01-01)

Long-term survival and clinical outcomes following direct-acting antiviral (DAA) treatment in HCV decompensated cirrhosis in Brazil: a real-world study
by: Gustavo H. Pereira, et al.
Published: (2022-09-01)

Efficacy and safety of glecaprevir and pibrentasvir in Japanese patients with hepatitis C virus infection aged 75 years or older
by: Yuri Komaki, et al.
Published: (2022-04-01)

Obstacles to successful treatment of hepatitis C in uninsured patients from a minority population
by: Alexandra DeBose-Scarlett, et al.
Published: (2018-06-01)

Platelets as an Extra-Hepatic Reservoir of Hepatitis C Virus RNA: A Prospective Study
by: Pradheer Gupta, et al.
Published: (2018-12-01)

Successful Eradication of Hepatitis C Virus by Interferon-Free Regimens in Two Patients with Advanced Liver Fibrosis following Kidney Transplantation
by: Reina Sasaki, et al.
Published: (2016-05-01)

Sofosbuvir and Daclatasvir in Mono- and HIV-coinfected Patients with Recurrent Hepatitis C After Liver Transplant
by: Lluís Castells, et al.
Published: (2017-01-01)

Concordance of sustained virologic response at weeks 4, 12 and 24 post-treatment of hepatitis C in the era of new oral direct-acting antivirals: A concise review
by: Sarah V. Burgess, et al.
Published: (2016-03-01)

The study of Alpha-Fetoprotein (AFP) levels before and after treatment of Hepatitis C Virus in Egyptian patients
by: Mohey Eldin Hassan Shikhoun*, et al.
Published: (2024-07-01)

Prognosis Following Sustained Virologic Response in Korean Chronic Hepatitis C Patients Treated with Sofosbuvir-Based Treatment: Data from a Multicenter Prospective Observational Study up to 7 Years
by: Yewan Park, et al.
Published: (2024-07-01)

Beyond genotype‐4: Direct‐acting antiviral agents in patients with chronic hepatitis C infection from the Eastern Province of Saudi Arabia
by: Mona H. Ismail
Published: (2024-01-01)

Depressive and Anxious Symptoms in Hepatitis C Virus Infected Patients Receiving DAA-Based Therapy
by: Claudia Monica Danilescu, et al.
Published: (2021-11-01)

Perceived Stress in Hepatitis C Virus Infected Patients under the DAA-Based Therapy
by: Claudia Monica Danilescu, et al.
Published: (2022-05-01)

Treatment Outcomes of Sofosbuvir/Velpatasvir/Voxilaprevir in Direct-Acting Antiviral-Experienced Hepatitis C Virus Patients: A Systematic Review and Meta-Analysis
by: Pooja Devan, et al.
Published: (2023-06-01)

Direct-Acting Antivirals Reduce the De Novo Development of Esophageal Varices in Patients with Hepatitis C Virus Related Liver Cirrhosis
by: Yung-Yu Hsieh, et al.
Published: (2023-01-01)

Long-term durability of sustained virologic response for hepatitis C virus infection in solid organ transplant recipients receiving direct-acting antivirals
by: Chen-Hua Liu, et al.
Published: (2023-08-01)

Does Hepatitis C Virus Treatment by Directly Acting Antivirals Obligate Shifting Patients with Type 2 Diabetes from Oral Hypoglycemic Drugs to Insulin Therapy?
by: Hagag RY, et al.
Published: (2022-04-01)

The long-term prospective study of patients with liver cirrhosis after elimination of the hepatitis C virus
by: E. A. Nabatchikova, et al.
Published: (2020-02-01)

Effect of Successful Direct Acting Antivirals Therapy on Liver Stiffness in Patients with Chronic HCV Infection
by: Ibrahim Anam Ezzelregal, et al.
Published: (2020-10-01)

The impact of achieving a sustained virological response with direct-acting antivirals on serum autotaxin levels in chronic hepatitis C patients
by: Shereen Abou Bakr Saleh, et al.
Published: (2020-11-01)

Five-Year Prospective Follow-Up of Patients with Hepatitis C Virus Infection Treated with Direct-Acting Antiviral Agents
by: Zhang Y, et al.
Published: (2025-01-01)

Surveillance and management of hepatocellular carcinoma after treatment of hepatitis C with direct-acting antiviral drugs
by: Caiyun Yang, et al.
Published: (2025-03-01)

Real-World Clinical Efficacy and Tolerability of Direct-Acting Antivirals in Hepatitis C Monoinfection Compared to Hepatitis C/Human Immunodeficiency Virus Coinfection in a Community Care Setting
by: Vijay Gayam, et al.
Published: (2018-11-01)

Repeated Measurement of FIB-4 to Predict Long-Term Risk of HCC Development Up to 10 Years After SVR
by: Zou Y, et al.
Published: (2022-12-01)

Risk factors for liver‐related mortality of patients with hepatitis C virus after sustained virologic response to direct‐acting antiviral agents
by: Nobuhiro Hattori, et al.
Published: (2022-10-01)